Abstract
Structure-based pharmacophore mapping, drug-likeness and ADMET profiles were used as tools in our virtual screening process, in addition to molecular docking studies that were used to find novel CDK4/6 inhibitors with different heterocyclic scaffolds, having appropriate physicochemical parameters and non toxic. Aim of this work is to search for new promising CDK4/6 inhibitors, that have a great potential to be approved as clinically useful drugs in cancer therapy. Six promising hits were retrieved after applying virtual screening filters, these hits were subjected to molecular docking studies and were compared with the approved CDK4/6 inhibitor drug (palbociclib). Finally, we can conclude that they have a great potential to target CDK4/6 in a closely similar manner as palbociclib, in addition to their predicted good ADMET properties, they can be considered as novel hopeful leads for CDK4/6 inhibition and deserve further clinical investigations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Malumbres, M., Genome Biol., 2014, vol. 15, pp. 1–10. http://genomebiology.com/2014/15/6/122.
Harper, J. and Adams, P., Chem. Rev., 2001, vol. 101, pp. 2511–2526.
Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao H., Yu M., Lin J., Cui Q. Int. J. Mol. Sci. 2020, vol. 21, p. 1960. https://doi.org/10.3390/ijms21061960
Sourav, K., Gaurav, J., Anjana, M., and Raj, K., Eur. J. Med. Chem., 2017, vol. 142, pp. 424–458.
Neil, J. and Geoffrey, I.S., Expert Opin. Ther. Targets, 2010, vol. 14, pp. 1199–1212.
Aggarwal, P., Vaites, L.P., Kim, J.K., Mellert, H., Gurung, B., Nakagawa, H., Herlyn, M., Hua, X., Rustgi, A.K., and McMahon, S.B., Cancer Cell, 2010, vol. 18, pp. 329–340.
Ugale, V.G. and Bari, S.B., SAR QSAR Environ. Res., 2016, vol. 27, pp. 125–145.
Meetei, P.A., Rathore, R.S., Prabhu, N.P., and Vindal, V., Springer Plus, 2016, vol. 5, p. 965.
Tuccinardi, T., Poli, G., Corchia, I., Granchi, C., Lapillo, M., Macchia, M., Minutolo, F., Ortore, G., and Martinelli, A., Mol. Inform., 2016, vol. 35, pp. 434–439.
Cho, Y.S., Angove, H., Brain, C., Chen, C.H., Cheng, H., Cheng, R., Chopra, R., Chung, K., Congreve, M., Dagostin, C., Davis, D.J., Feltell, R., Giraldes, J., Hiscock, S.D., Kim, S., Kovats, S., Lagu, B., Lewry, K., Loo, A., Lu, Y., Luzzio, M., Maniara, W., McMenamin, R., Mortenson, P.N., Benning, R., O’Reilly, M., Rees, D.C., Shen, J., Smith, T., Wang, Y., Williams, G., Woolford, A.J., Wrona, W., Xu, M., Yang, F., and Howard, S., ACS Med. Chem. Lett., 2012, vol. 17, pp. 445–449.
Reddy, M.V., Akula, B., Cosenza, S.C., Athuluridivakar, S., Mallireddigari, M.R., Pallela, V.R., Billa, V.K., Subbaiah, D.R., Bharathi, E.V., Vasquez-Del Carpio, R., Padgaonkar, A., Baker, S.J., and Reddy, E.P., J. Med. Chem., 2014, vol. 13, pp. 578–599.
Tadesse, S., Yu, M., Mekonnen, L.B., Lam, F., Islam, S., Tomusange, K., Rahaman, M.H., Noll, B., Basnet, S.K., Teo, T., Albrecht, H., Milne, R., and Wang, S., J. Med. Chem., 2017, vol. 9, pp. 1892–1915.
Tadesse, S., Yu, M., Kumarasiri, M., Le, B.T., and Wang, S., Cell Cycle, 2015, vol. 14, pp 3220–3230.
Hirai, H., Shimomura, T., Kobayashi, M., Eguchi, T., Taniguchi, E., Fukasawa, K., Machida, T., Oki, H., Arai, T., Ichikawa, K., Hasako, S., Haze, K., Kodera, T., Kawanishi, N., Takahashi-Suziki, I., Nakatsuru, Y., Kotani, H., and Iwasawa, Y., Cell Cycle, 2010, vol. 15, pp.1590–1600.
Fry, D., Bedford, D.C., Harvey, P.H., Fritsch, A., Keller, P.R., Wu, Z., Dobrusin, E., Leopold, W.R., Fattaey, A., and Garrett, M.D., J. Biol. Chem., 2001, vol 18, pp. 16617–16623.
Molecular Operating Environment (MOE), C.C.G.I., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2013. https://www.chemcomp.com/ MOE-Molecular_Operating_Environment.htm. Accessed January 4, 2018.
Sanders, M.P., Barbosa, A.J., Zarzycka, B., Nicolaes, G.A., Klomp, J.P., de Vlieg, J., and del Rio, A., J. Chem. Inf. Model., 2012, vol. 52, pp. 1607–1620.
Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J., Adv. Drug Deliv. Rev., 2001, vol. 46, pp. 3–26.
Feixiong, C., Weihua, L., Yadi, Z., Jie, S., Zengrui, W., Guixia, L., Philip, W.L., and Yun, T., J. Chem. Inf. Model., 2012, vol. 52, pp. 3099–3105.
Simon-Szabó, L., Kokas, M., Greff, Z., Boros, S., Bánhegyi, P., Zsákai, L., Szántai-Kis, C., Vantus, T., Mandl, J., Bánhegyi, G., Vályi-Nagy, I., Örfi, L., Ullrich, A., Csala, M., and Kéri, G., Bioorg. Med. Chem. Lett., 2016, vol. 26, p. 424.
Kraker, A.J., Hartl, B.G., Amar, A.M., Barvian, M.R., Showalter, H.D., and Moore, C.W., Biochem. Pharmacol., 2000, vol. 60, p. 885.
Chen, L., Yap, J.L., Yoshioka, M., Lanning, M.E., Fountain, R.N., Raje, M., Scheenstra, J.A., Strovel, J.W., and Fletcher, S., ACS Med. Chem. Lett., 2015, vol. 6, p. 764.
Tan, L., Akahane, K., McNally, R., Reyskens, K.M., Ficarro, S.B., Liu, S., Herter-Sprie, G.S., Koyama, S., Pattison, M.J., Labella, K., Johannessen, L., Akbay, E.A., Wong, K.K., Frank, D.A., Marto, J.A., Look, T.A., Arthur, J.S., Eck, M.J., and Gray, N.S., J. Med. Chem., 2015, vol. 58, p. 16:6589.
ACKNOWLEDGMENT
Appreciated thanks to Taif University Researchers Supporting Project number (TURSP-2020/35), Taif University, Taif, Saudi Arabia.
Funding
This work was financially supported by Taif University Researchers Supporting Project number (TURSP-2020/35), Taif University, Taif, Saudi Arabia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
COMPLIANCE WITH ETHICAL STANDARDS
No experiments have been conducted on humans or animals in this research work.
Conflict of Interests
The authors declare that there is no conflict of interest.
Supplementary Information
Rights and permissions
About this article
Cite this article
Belal, A. 3D-Pharmacophore Modeling, Molecular Docking, and Virtual Screening for Discovery of Novel CDK4/6 Selective Inhibitors. Russ J Bioorg Chem 47, 317–333 (2021). https://doi.org/10.1134/S1068162021330013
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1068162021330013